Maurizio Zangari

List of Publications by Year
in descending order

187	6,978	101496	60583
papers	citations	36 h-index	81 g-index

188	188	188	5996
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The molecular classification of multiple myeloma. Blood, 2006, 108, 2020-2028.	0.6	997
2	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 2007, 109, 2276-2284.	0.6	831
3	Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 2002, 99, 1745-1757.	0.6	590
4	Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 2001, 98, 492-494.	0.6	524
5	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 2007, 138, 176-185.	1.2	304
6	Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology, 2001, 114, 822-829.	1.2	267
7	NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers. Cancer Cell, 2013, 23, 48-62.	7.7	232
8	Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents. Journal of Clinical Oncology, 2009, 27, 4865-4873.	0.8	200
9	Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British Journal of Haematology, 2001, 114, 600-607.	1.2	199
10	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 2005, 131, 71-73.	1.2	180
11	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood, 2016, 128, 1735-1744.	0.6	170
12	The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology, 2009, 84, 6-14.	2.0	132
13	Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica, 2006, 91, 192-9.	1.7	127
14	Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma. Clinical Cancer Research, 2004, 10, 88-95.	3.2	110
15	Thalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival. Clinical Lymphoma and Myeloma, 2003, 4, 32-35.	2.1	101
16	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical Cancer Research, 2017, 23, 1981-1987.	3.2	97
17	The Blood Coagulation Mechanism in Multiple Myeloma. Seminars in Thrombosis and Hemostasis, 2003, 29, 275-282.	1.5	78
18	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood, 2018, 132, 59-66.	0.6	75

#	Article	IF	Citations
19	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Advances, 2020, 4, 422-431.	2.5	66
20	Hemostatic Dysfunction in Paraproteinemias and Amyloidosis. Seminars in Thrombosis and Hemostasis, 2007, 33, 339-349.	1.5	64
21	Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 228-236.	0.2	63
22	Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. Journal of Clinical Oncology, 2010, 28, 132-135.	0.8	58
23	Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy, 2007, 7, 307-315.	1.1	57
24	The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica, 2017, 102, e364-e367.	1.7	57
25	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	5.8	54
26	A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica, 2011, 96, 333-336.	1.7	52
27	Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging. Biomaterials, 2018, 183, 67-76.	5.7	49
28	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1047-1053.	1.7	47
29	Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 109-114.	1.4	46
30	Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood, 2014, 123, 2504-2512.	0.6	45
31	Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. British Journal of Haematology, 2007, 137, 530-536.	1.2	44
32	Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treatment Reviews, 2012, 38, 968-980.	3.4	44
33	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	1.7	44
34	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood, 2015, 125, 3756-3759.	0.6	41
35	The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone, 2016, 86, 131-138.	1.4	39
36	Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. European Journal of Haematology, 2011, 86, 484-487.	1.1	38

#	Article	IF	Citations
37	BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2422-2432.	3.2	37
38	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American Journal of Hematology, 2017, 92, 739-745.	2.0	36
39	Daratumumab in highâ€risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British Journal of Haematology, 2020, 189, 67-71.	1.2	35
40	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. British Journal of Haematology, 2008, 141, 433-444.	1.2	33
41	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Medicine, 2020, 17, e1003323.	3.9	33
42	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical Cancer Research, 2018, 24, 2913-2919.	3.2	30
43	Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).. Blood, 2004, 104, 1480-1480.	0.6	29
44	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer Journal, 2020, 10, 70.	2.8	27
45	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica, 2017, 102, e313-e316.	1.7	26
46	Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia, 2018, 32, 2435-2444.	3.3	26
47	Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagulation and Fibrinolysis, 2007, 18, 595-598.	0.5	25
48	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer Journal, 2019, 9, 62.	2.8	23
49	Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).. Blood, 2005, 106, 3490-3490.	0.6	23
50	Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?. Blood Coagulation and Fibrinolysis, 2013, 24, 311-316.	0.5	22
51	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptorâ€“T Cell Therapy for Hematological Malignant Neoplasms. JAMA Network Open, 2022, 5, e228161.	2.8	22
52	Monitoring treatment response and disease progression in myeloma with circulating cellâ€free DNA. European Journal of Haematology, 2021, 106, 230-240.	1.1	21
53	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 108.	6.9	20
54	Mesenchymal stem cells gene signature in highâ€risk myeloma bone marrow linked to suppression of distinct IGFBP2â€expressing small adipocytes. British Journal of Haematology, 2019, 184, 578-593.	1.2	18

#	Article	IF	Citations
55	Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.. Blood, 2004, 104, 77-77.	0.6	18
56	Immunomodulatory drugs in multiple myeloma. Expert Opinion on Investigational Drugs, 2005, 14, 1411-1418.	1.9	16
57	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	2.5	16
58	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	2.5	14
59	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical Cancer Research, 2017, 23, 2665-2672.	3.2	13
60	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics, 2019, 9, 4756-4763.	4.6	12
61	Addition of Bortezomib (Velcadeâ„¢) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).. Blood, 2004, 104, 929-929.	0.6	12
62	Mechanisms of Thrombosis in Paraproteinemias: The Effects of Immunomodulatory Drugs. Seminars in Thrombosis and Hemostasis, 2012, 38, 768-779.	1.5	11
63	Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone, 2014, 61, 39-43.	1.4	11
64	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of Bone and Mineral Research, 2017, 32, 1261-1266.	3.1	9
65	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers, 2021, 13, 4019.	1.7	9
66	Protective Effect of VELCADEÂ® on Thalidomide-Associated Deep Vein Thrombosis (DVT).. Blood, 2004, 104, 4914-4914.	0.6	8
67	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. Blood, 2016, 128, 4431-4431.	0.6	8
68	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. Blood, 2016, 128, 4516-4516.	0.6	8
69	Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Research, 2022, 32, 1343-1354.	2.4	8
70	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. Blood, 2015, 126, 20-20.	0.6	7
71	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy, 2016, 8, 367-384.	1.0	6
72	Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transplant Infectious Disease, 2019, 21, e13052.	0.7	6

#	Article	IF	Citations
73	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia, 2022, 36, 591-595.	3.3	6
74	Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.. Blood, 2005, 106, 423-423.	0.6	6
75	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of Clinical Medicine, 2022, 11, 1640.	1.0	6
76	Chimeric Antigen Receptor T-Cell Therapy in Multiple Myelomaâ€"Challenges and Potential Solutions. JAMA Oncology, 2022, 8, 823.	3.4	6
77	Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma. Current Pharmaceutical Biotechnology, 2006, 7, 449-453.	0.9	5
78	PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational Medicine, 2021, 69, 103290.	1.2	5
79	Bleeding Disorders Associated with Cancer Dysproteinemias. Cancer Treatment and Research, 2009, 148, 295-304.	0.2	5
80	A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.. Blood, 2006, 108, 111-111.	0.6	5
81	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. Blood, 2014, 124, 3409-3409.	0.6	5
82	Firstâ€•versus secondâ€generation Bruton tyrosine kinase inhibitors in WaldenstrÃ¶m's Macroglobulinemia: A systematic review and metaâ€•analysis. American Journal of Hematology, 2022, 97, 942-950.	2.0	5
83	Activated protein C resistance as measured by residual factor V after RussellÊ¼s Viper Venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagulation and Fibrinolysis, 2011, 22, 420-423.	0.5	4
84	Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice. Endocrinology, 2018, 159, 1561-1569.	1.4	4
85	Innate Biomineralization. International Journal of Molecular Sciences, 2020, 21, 4820.	1.8	4
86	Bone remineralization of lytic lesions in multiple myeloma â€“ The Arkansas experience. Bone, 2021, 146, 115876.	1.4	4
87	Persistent bone marrow minimal residual disease as a â€œhighâ€•riskâ€•disease feature in multiple myeloma. American Journal of Hematology, 2021, 96, E341-E344.	2.0	4
88	Highâ€•risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British Journal of Haematology, 2021, 195, 283-286.	1.2	4
89	EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. Blood, 2019, 134, 4569-4569.	0.6	4
90	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. Blood, 2014, 124, 4775-4775.	0.6	4

#	Article	IF	Citations
91	Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies. Blood, 2021, 138, 566-566.	0.6	4
92	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	2.0	4
93	Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo. Journal of Bone Oncology, 2018, 12, 19-22.	1.0	3
94	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone, 2019, 121, 134-138.	1.4	3
95	Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies. Blood, 2018, 132, 1882-1882.	0.6	3
96	Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma. Blood, 2018, 132, 408-408.	0.6	3
97	Late Relapsing Multiple Myeloma â‰¥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. Blood, 2020, 136, 11-12.	0.6	3
98	Curing Multiple Myeloma (MM) with Total Therapy (TT). Blood, 2014, 124, 195-195.	0.6	3
99	Waldenstrom's Macroglobulinemia Associated Bone Disease the UAMS Experience. Blood, 2014, 124, 2999-2999.	0.6	3
100	Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling. Blood, 2014, 124, 3418-3418.	0.6	3
101	Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients. Blood, 2016, 128, 3304-3304.	0.6	3
102	Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics. BioMed Research International, 2015, 2015, 1-2.	0.9	2
103	Effect of lowâ€dose bortezomib on bone formation in smouldering multiple myeloma. British Journal of Haematology, 2019, 184, 308-310.	1.2	2
104	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, 106, 0-0.	1.7	2
105	The Mutational Landscape of Primary Plasma Cell Leukemia. Blood, 2018, 132, 114-114.	0.6	2
106	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. Blood, 2019, 134, 4333-4333.	0.6	2
107	Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.. Blood, 2004, 104, 2884-2884.	0.6	2
108	The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.. Blood, 2005, 106, 510-510.	0.6	2

#	Article	IF	Citations
109	Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.. Blood, 2007, 110, 548-548.	0.6	2
110	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. Blood, 2015, 126, 1806-1806.	0.6	2
111	Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. Blood, 2015, 126, 1808-1808.	0.6	2
112	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Blood, 2015, 126, 2979-2979.	0.6	2
113	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. Blood, 2016, 128, 3278-3278.	0.6	2
114	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8514-8514.	0.8	2
115	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. Blood, 2015, 126, 3181-3181.	0.6	2
116	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. Blood, 2016, 128, 115-115.	0.6	2
117	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. Blood, 2019, 134, 3309-3309.	0.6	2
118	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. Blood, 2020, 136, 44-44.	0.6	2
119	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, e20031-e20031.	0.8	1
120	Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. Blood, 2018, 132, 110-110.	0.6	1
121	A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.. Blood, 2006, 108, 3393-3393.	0.6	1
122	Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies. Blood, 2012, 120, 4073-4073.	0.6	1
123	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2014, 124, 2128-2128.	0.6	1
124	Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma. Blood, 2014, 124, 725-725.	0.6	1
125	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). Blood, 2015, 126, 1843-1843.	0.6	1
126	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. Blood, 2015, 126, 369-369.	0.6	1

#	Article	IF	Citations
127	The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. Blood, 2015, 126, 372-372.	0.6	1
128	Thymus-Derived PTH (TPTH) Is Increased after Thyroparathyroidectomy in C57BL6/Kalwrij Mice and Modulates Mouse Sensitivity to 5TGM1 Myeloma Cell Line. Blood, 2015, 126, 5335-5335.	0.6	1
129	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. Blood, 2016, 128, 2065-2065.	0.6	1
130	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. Blood, 2016, 128, 3266-3266.	0.6	1
131	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. Blood, 2016, 128, 377-377.	0.6	1
132	The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does.. Blood, 2005, 106, 1157-1157.	0.6	1
133	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Blood, 2015, 126, 3182-3182.	0.6	1
134	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. Blood, 2016, 128, 117-117.	0.6	1
135	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. Blood, 2016, 128, 4416-4416.	0.6	1
136	Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models. Blood, 2016, 128, 5664-5664.	0.6	1
137	Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance. Blood, 2018, 132, 4465-4465.	0.6	1
138	Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. Blood, 2018, 132, 1906-1906.	0.6	1
139	An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. Blood, 2018, 132, 4489-4489.	0.6	1
140	Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Blood, 2021, 138, 4110-4110.	0.6	1
141	Anticoagulation regimens for thalidomide and lenalidomide. Clinical Advances in Hematology and Oncology, 2006, 4, 658-9.	0.3	1
142	An Outbreak of Respiratory Syncytial Virus Infections in an Outpatient Cancer Unit: Clinical Characteristics and Molecular Investigations. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
143	A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell Transplantation, 2019, 28, 1624-1631.	1.2	0
144	Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e551-e555.	0.2	0

#	Article	IF	Citations
145	Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).. Blood, 2004, 104, 940-940.	0.6	0
146	Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.. Blood, 2004, 104, 934-934.	0.6	0
147	Metaphase Cytogenetic Abnormalities (M-CA) and Interphase FISH for Deletion 13 (FISH 13) in Total Therapy 2 (TT 2): Follow up Observation among? 380 Patients with Newly Diagnosed Multiple Myeloma (MM).. Blood, 2004, 104, 4935-4935.	0.6	0
148	Serum Concentrations of Vitamin B-12 and Alkaline Phosphatase in Newly Diagnosed Multiple Myeloma Patients.. Blood, 2005, 106, 5110-5110.	0.6	0
149	Variables Predicting for Poor Mobilization of Peripheral Blood Stem Cells (PBSC) in Newly Diagnosed Myeloma Patients, Treated on TT-2 Protocol.. Blood, 2005, 106, 1981-1981.	0.6	0
150	Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.. Blood, 2005, 106, 1152-1152.	0.6	0
151	Acquired Resistance to Activated Protein C (aAPCR) Is Associated with Increased Risk of Deep Vein Thrombosis in Multiple Myeloma.. Blood, 2005, 106, 3484-3484.	0.6	0
152	Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs â€œDiscontinuousâ€•Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).. Blood, 2005, 106, 1153-1153.	0.6	0
153	Stroke in a Multiple Myeloma Cohort.. Blood, 2007, 110, 4772-4772.	0.6	0
154	Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma. Blood, 2014, 124, 2079-2079.	0.6	0
155	Surgical Control/Cure of 5TGM1 Murine Multiple Myeloma Model By Thyroparathyroidectomy. Blood, 2014, 124, 3387-3387.	0.6	0
156	Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt. Blood, 2014, 124, 2078-2078.	0.6	0
157	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. Blood, 2014, 124, 3407-3407.	0.6	0
158	Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study. Blood, 2014, 124, 5770-5770.	0.6	0
159	Outcomes of Autologous Transplantation for Treatment-Related AML and MDS in Previously Treated Multiple Myeloma Patients (pts). Blood, 2015, 126, 1997-1997.	0.6	0
160	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. Blood, 2015, 126, 724-724.	0.6	0
161	Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma. Blood, 2015, 126, 2982-2982.	0.6	0
162	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. Blood, 2015, 126, 4173-4173.	0.6	0

#	Article	IF	Citations
163	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 5395-5395.	0.6	0
164	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	0.6	0
165	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. Blood, 2016, 128, 2064-2064.	0.6	0
166	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. Blood, 2016, 128, 4438-4438.	0.6	0
167	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. Blood, 2018, 132, 4457-4457.	0.6	0
168	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. Blood, 2018, 132, 4441-4441.	0.6	0
169	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. Blood, 2018, 132, 4468-4468.	0.6	0
170	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. Blood, 2018, 132, 3185-3185.	0.6	0
171	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. Blood, 2018, 132, 4471-4471.	0.6	0
172	Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes. Blood, 2018, 132, 4448-4448.	0.6	0
173	Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors. Blood, 2018, 132, 1929-1929.	0.6	0
174	The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells. Blood, 2019, 134, 4412-4412.	0.6	0
175	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 508-508.	0.6	0
176	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. Blood, 2019, 134, 4379-4379.	0.6	0
177	The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells. Blood, 2019, 134, 4390-4390.	0.6	0
178	Eltrombopag Following Chemotherapy and G-CSF+/- Plerixafor for Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Lymphoma and Myeloma Patients. Blood, 2019, 134, 5638-5638.	0.6	0
179	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. Blood, 2021, 138, 2713-2713.	0.6	0
180	N-Cadherin Stabilizes Î²-Catenin and Promotes Î²-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma. Blood, 2021, 138, 1572-1572.	0.6	0

#	Article	IF	Citations
181	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. Blood, 2021, 138, 1627-1627.	0.6	0
182	Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma. Blood, 2020, 136, 2-2.	0.6	0
183	Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT. Blood, 2020, 136, 24-24.	0.6	0
184	An Improved Animal Model of Multiple Myeloma Bone Disease. Blood, 2020, 136, 31-31.	0.6	0
185	CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction. Blood, 2020, 136, 21-21.	0.6	0
186	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American Journal of Hematology, 2022, 97, .	2.0	0
187	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, , .	1.7	0